In 10 years, Miles for Myeloma has raised $2.4 million to fight the disease

October 9, 2014

Fueled by the more than $2.4 million donated by patients, families and other Miles for Myeloma supporters, Dr. Abonour and his colleagues in the multiple myeloma program at the IU Melvin and Bren Simon Cancer Center have helped win approval of new drugs, developed methods to alleviate debilitating symptoms of the disease and illuminated how myeloma hijacks the body’s normal systems.

Their work, combined with the efforts of researchers elsewhere, is paying off: Survival rates for myeloma have doubled in the last decade. But more must be done. The average patient still only lives a little more than seven years after symptoms develop.

“When you have a rare cancer and the cancer behaves differently in each patient, it is difficult to come up with a one-size-fits-all treatment,” says Dr. Abonour, a professor of medicine at the IU School of Medicine. “What I mean is that we need to study each patient carefully so we can come up with the right treatment for each patient. That is why research is so important.”